Fig. 2.

Flow chart of population enrollment. This flowchart depicts how the 278 ocrelizumab-treated patients with relapsing–remitting multiple sclerosis (RRMS) were identified. The source population was all patients with multiple sclerosis (MS) treated with ocrelizumab in 9 Italian centers during the period between January 2020 and June 2021. We excluded patients who did not meet the inclusion criteria, who denied their consent to participate or with incomplete data on electronical medical records. EID, extended interval dosing; SID, standard interval dosing; MS, multiple sclerosis; OCR, ocrelizumab